<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01901159</url>
  </required_header>
  <id_info>
    <org_study_id>BP28433</org_study_id>
    <secondary_id>2012-002710-39</secondary_id>
    <nct_id>NCT01901159</nct_id>
  </id_info>
  <brief_title>A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, open-label, cross-over study will assess the bioavailability and safety of&#xD;
      RO4995819 in healthy volunteers. Volunteers will receive two different formulations (tablet&#xD;
      and capsule) of the study drug under fed and fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability: Plasma concentration of RO4995819</measure>
    <time_frame>Approximately 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: incidence of adverse events</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>RO4995819 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>RO4995819 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4995819</intervention_name>
    <description>Oral doses of RO4995819 (tablet)</description>
    <arm_group_label>RO4995819 tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4995819</intervention_name>
    <description>Oral doses of RO4995819 (capsule)</description>
    <arm_group_label>RO4995819 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy non-smoking male and female volunteers, 18 to 65 years of age, inclusive.&#xD;
&#xD;
          -  A body mass index (BMI) between 18 to 30 kg/m2, inclusive.&#xD;
&#xD;
          -  Able to participate and willing to give written informed consent and to comply with&#xD;
             the study restrictions.&#xD;
&#xD;
          -  Willing not to participate in any other clinical trial with an investigational drug or&#xD;
             device for at least 3 months following the follow up visit.&#xD;
&#xD;
          -  Male volunteers and their partners of childbearing potential must use two adequate&#xD;
             methods of contraception. Female volunteers who are not either surgically sterile or&#xD;
             postmenopausal must commit to use two adequate methods of contraception throughout the&#xD;
             study and until at least 5 months after last dosing.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant gastrointestinal, renal, hepatic,&#xD;
             broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological,&#xD;
             hematological or allergic disease, metabolic disorder or cancer&#xD;
&#xD;
          -  Significant past or present disorders of the central nervous system, psychiatric&#xD;
             disorders, behavioral disturbances&#xD;
&#xD;
          -  Diseases or medical conditions that are capable of altering the absorption, metabolism&#xD;
             or elimination of drugs&#xD;
&#xD;
          -  Any condition or disease detected during the medical interview / physical examination&#xD;
             that would render the volunteer unsuitable for the study, place the volunteer at undue&#xD;
             risk or interfere with the ability of the volunteer to complete the study in the&#xD;
             opinion of the Investigator&#xD;
&#xD;
          -  Clinically significant abnormalities in laboratory test results&#xD;
&#xD;
          -  Confirmed resting pulse rate greater than 90 or less than 40 beats per minute (bpm) at&#xD;
             screening&#xD;
&#xD;
          -  Confirmed systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and&#xD;
             diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg at screening&#xD;
&#xD;
          -  Any major illness within the 4 weeks prior to dosing or any acute disease state within&#xD;
             7 days of study start&#xD;
&#xD;
          -  Any confirmed allergic reaction against any drug or multiple allergies&#xD;
&#xD;
          -  Any suspicion or history of alcohol abuse and/or consumption of other drugs of abuse&#xD;
&#xD;
          -  Infection with hepatitis B, hepatitis C virus, or HIV 1 and HIV 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>July 3, 2013</study_first_submitted>
  <study_first_submitted_qc>July 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2013</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

